Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab SC Device vs Vial in HER2+ Early Breast Cancer
NCT02194166Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Started Jul 2014; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02194166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194166.